AYTU

Dopo l'orario di chiusura: 1.23 0.01 +0.82%

Aytu Biopharma Inc (AYTU)

Panoramica Notizia Cronologia dei prezzi Financials Perché AYTU Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Aytu Biopharma Inc Stock (AYTU) Company Profile

Aytu Biopharma Inc

Healthcare (1169)

(720) 437-6580

7900 E. UNION AVENUE, DENVER

@aytubioscience

Prossima data di guadagno

Ultimi documenti SEC

AYTU's Discussions on Twitter

Confronta AYTU con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AYTU Aytu Biopharma Inc	1.22	7.53M	93.76M	-13.68M	8.77M	-2.63
ZTS Zoetis Inc	160.06	71.67B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.03	47.44B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.19	46.08B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.46	18.86B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.36	13.97B	612.78M	-86.37M	-62.91M	-0.87

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-03-30	Iniziato	Cantor Fitzgerald	Overweight
2020-05-29	Iniziato	H.C. Wainwright	Buy

Aytu Biopharma Inc Borsa (AYTU) Ultime notizie

Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc Stock (AYTU) Company Profile

Confronta AYTU con altri titoli

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Aytu Biopharma Inc Borsa (AYTU) Ultime notizie

AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com Canada

Insider Buying: Joshua Disbrow Acquires 15,000 Shares of Aytu Bi - GuruFocus.com

Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock - Investing.com

Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock By Investing.com - Investing.com South Africa

AYTU BIOPHARMA CEO Acquires 15,000 Shares - TradingView

Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 - ACCESS Newswire

Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance - ACCESS Newswire

Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue - ACCESS Newswire

Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN

AYTU stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia

AYTU stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa

Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 - ACCESS Newswire

Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings - MSN

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row - ACCESS Newswire

Aytu BioPharma’s Imminent Breakthrough: Can It Reach Profitability? - Mi Valle

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Stro - GuruFocus.com

Aytu BioScience Earnings Call: Growth Amid Challenges - TipRanks

Denver biotech cuts $500K check when it parted ways with its CFO - The Business Journals

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... By GuruFocus - Investing.com Canada

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript - Insider Monkey

Aytu BioPharma Reports Strong Q2 Earnings Growth - TipRanks

Aytu BioPharma Inc. (AYTU) reports earnings - Quartz

AYTU BIOPHARMA, INC SEC 10-Q Report - TradingView

Aytu BioPharma Reports Fiscal 2025 Second Quarter Results - TradingView

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results - ACCESS Newswire

Aytu BioPharma Turns Profitable: Key Portfolio Growth Drives Q2 Transformation - StockTitan

Aytu BioPharma Reports First Quarter 2022 Financial Results - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 - Galveston County Daily News

Aytu BioPharma Earnings Alert: Key Financial Results Coming February 12What to Watch - StockTitan

Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021 - ACCESS Newswire

Aytu BioPharma to Present at LD Micro Main Event XVI Conference - ACCESS Newswire

Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 - ACCESS Newswire

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - ACCESS Newswire

Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - ACCESS Newswire

Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso - ACCESS Newswire

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year - ACCESS Newswire

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - ACCESS Newswire

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - ACCESS Newswire

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - ACCESS Newswire

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results - ACCESS Newswire

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire

Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth - Simply Wall St

Aytu BioPharma CEO to Present Growth Strategy at Lytham Partners Healthcare Summit - StockTitan

Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest - Defense World

An unknown company affiliated with Jonathan Hughes acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com

Aytu BioPharma, Inc. (NASDAQ:AYTU) Is About To Turn The Corner - Simply Wall St

Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AYTU